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Abstract
In spite of the considerable amount of experimental, clinical and epidemiological research about the
consumption of red meat, total fats, saturated/unsaturated fatty acids and cholesterol with regard
to the risk of developing colorectal cancer (CRC), the issue remains controversial. The general
belief is a reduction of red meat intake, and subsequent nutritional advice usually strongly
recommends this. Paradoxically, beef together with whole milk and dairy derivatives, are almost
the only sources for conjugated linoleic acid (CLAs) family. Furthermore CLAs are the only natural
fatty acids accepted by the National Academy of Sciences of USA as exhibiting consistent antitumor
properties at levels as low as 0.25 – 1.0 per cent of total fats. Beside CLA, other polyunsaturated
fatty acids (PUFA) belonging to the essential fatty acid (EFA) n-3 family, whose main source are fish
and seafood, are generally believed to be antipromoters for several cancers. The purpose of this
work is to critically analyze the epidemiological and experimental evidence by tentatively assuming
that the reciprocal proportions of saturated fats (SA) plus cholesterol (CH) versus CLAs levels in
fatty or lean beef may play an antagonistic role underlying the contradictory effects reported for
red meats consumption and CRC risk. Recent results about meat intake and risk for CRC in
Argentina have shown an unexpected dual behaviour related to the type of meats. Fatty meat
derivatives, such as cold cuts and sausages, mainly prepared from fatty beef (up to 37% fat) were
associated with higher risk, whereas high consumption of lean beef (< 15% fat) behaved as a
protective dietary habit. CLA is located in the interstitial, non-visible, fat evenly distributed along
muscle fibres as well as in subcutaneous depots. Visible fat may be easily discarded during the meal,
whereas interstitial fats will be eaten. The remaining intramuscular fat in lean meats range from 25
to 50 g/Kg (2.5 to 5%). The proportion of CLA/SA+CH for lean beef eaters is 0.09 and the fatty
mets 0.007 (g/100 g). As a consequence, the beneficial effects of minor amounts of CLA may be
relatively enhanced in lean meat compared to fatty meat sub-products which contain a substantial
amount of saturated fatty acids and cholesterol, as in cold cuts and cow viscera.
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Background
Conjugated linoleic acid (CLA) is a wide term which
groups together a mixture of positional and geometric iso-
mers of C 18:2 fatty acids having conjugated, or contigu-
ous, double bounds. These fatty acids arise along the
ruminal process which ends with full saturation into
stearic acid, a stepped pathway carried out by rumen
bacteria.
These naturally occurring groups of dienoic derivatives of
linoleic acid are incorporated into the fat in beef and milk
of ruminants before the saturation process has been com-
pleted. Numerous beneficial effects are attributed to CLA,
as in slowing down or even preventing tumor develop-
ment. CLA decreases body fat storage in animal models
[1] and promotes cardiovascular protection against athe-
roesclerosis [2]. A growing bulk of evidence shows that
CLA, mainly as cis-9, trans-11, 18:2 n-6 derivatives, con-
sistently produced antitumor effects, thus reducing the
incidence, progression, number of metastases and tumor
burden in rats and in murine models of mammary gland,
colon, forestomach, skin and prostate tumorigenesis [3].
The evidence became so convincing that the National
Academy of Science advised in 1996 that "Conjugated
linoleic acid (CLA) is the only fatty acid shown unequivo-
cally to inhibit carcinogenesis in experimental animals"
[4]. Beside CLA, other polyunsaturated fatty acids (PUFA)
belonging to the essential fatty acid (EFA) n-3 family,
whose main source are fish and seafood, are generally
believed to act as antipromoters for several cancers.
Interestingly enough for those populations having little o
negligible fish intake as in the case of the mediterranean
population of Argentina [5,6], CLA remains the only
source of beneficial fatty acids with respect to tumor pre-
vention and cardiovascular protection.
The natural source of CLA are red meats and fatty dairy
products, which are mainly bovine derivatives. However,
these foods are also heavily suspected to be related to the
higher risk of developing colorectal cancer (CRC) in
humans. Indeed, as a consequence of a huge, and often
contradictory, epidemiological, clinical and experimental
amount of research, general advice has been sent to the
population at large, suggesting that fatty beef, and to a
lesser extent, whole fatty dairy derivatives, should be eaten
less frequently, whereas the amount of dietary n-3 PUFAs
might be increased.
CRC in humans continues to be a major challenge, since
death rates due to colon carcinoma have not diminished
appreciably within the past decades [7]. CRC is a major
disease in Western populations, and diet may account for
approximately 35% of the cases. The Argentinean food
pattern, rich in beef and fats and poor in fibres and fish,
may be related to an increased CRC risk. Our previous
case-control studies on Argentinian people were consist-
ent with these mentioned beliefs, showing that a high fre-
quency of heavily roasted meat was associate with
increased CRC risk. Saturated fatty acids and cholesterol
also seemed to play an important role in this risk [8].
However, further characterization of meat consumption
and risk for CRC by total intake as well as by different vari-
eties of meat showed an unexpected dual behaviour
related to the type of meats. Fatty meat derivatives, such as
cold cuts and sausages, mainly prepared from fatty beef
were consistently associated with higher risk, whereas
high consumption of lean beef behaved as a protective
dietary habit. High total meat consumption was not
related to an increased risk of CRC in our subjects, even
adjusting for energy and all macronutrients. Even though
that the CRC risk has been attributed to other factors, as
amount and varieties of nitrosocompounds [9] and heme
ring of hemoglobin [10], several extensive reviews point
to an increased risk linked somewhere to meat fat content.
Indeed, different kinds of meat have similar levels of pro-
tein, so the mayor difference may lay in other compo-
nents, for example, the amount and quality of lipid
components. High fat diets, rich in cholesterol and satu-
rated lipids, may favour cancer because of their high
caloric content, or they could lead to increased levels of
bile acids in the colonic rumen or a disbalance of the
essential fatty acids metabolism [11].
On the other hand, fats from bovine milk and meat con-
tain variable proportions of CLA. Interestingly, CLA is
located in the interstitial, non-visible, fat evenly distrib-
uted along muscle fibres as well as in subcutaneous
depots. Whereas the visible fat may be easily discarded
and not consumed during the meal, interstitial fats will be
eaten. The remaining invisible intramuscular total fat in
lean meats range from 25 to 50 g/Kg (2.5–5%) [12]. As a
consequence, beneficial effects of minor amounts of CLA
will be relatively enhanced in lean meat compared to fatty
meat sub-products since the latter contain thus a substan-
tial amount of saturated fatty acids and cholesterol, as in
cold cuts and cow viscera, diluting CLA.
In conclusion, whatever the beneficial or deleterious
effects of CLA and saturated fatty acids/cholesterol mech-
anisms are, in the ruminant meats mixed natural fats may
modulate opposite effects with regard to the risk of devel-
opment of CRC in humans, according to their relative
concentrations.
Presentation of the hypothesis
The aim of this review is to analyse the evidence demon-
strating that reciprocal proportions of CLA and saturated
fats/cholesterol may play an antagonistic role producingLipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/6
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contradictory or no effects, as in the case of beef meat and
dairy product intake with regard to risk of colon cancer.
Relative proportions of CLA and saturated fats/cholesterol 
in lean and fatty beefs meat
CLA concentrations in dairy products typically range from
2.9 to 8.92 mg/g fat, of which the 9-cis, 11-trans isomer
makes up to 73 to 93% of the total CLA. Low concentra-
tions of CLA are found in human blood and tissues [13].
The ratio between CLA and saturated fats plus cholesterol
in fatty and lean meats, is shown in table 1[14].
The levels of CLA in commercial beef (g) and dairy prod-
ucts (ml) ranged from 1.2 and 6.2 mg/g of fat and 0.001
– 4.3 mg/g respectively [15]. The Argentinian people eat
an average of 270 g of beef and beef derivatives per day.
This means roughly a daily consumption of almost 1 g of
CLA per day, possibly at levels of CLA which may exhibit
beneficial health effects according to the literature. It can
also be assumed that these minor amounts of CLA should
balance the huge amount of dietary saturated fatty acids
and cholesterol from beef and other sources of animal fat.
As it can be seen, in Table 1, lean meat has a ratio which
is double that of fatty meat.
Mechanism underlying the of action of CLA and saturated 
fats: CLA, Pro-oxidant or anti-oxidant?
Pioneering studies about the mechanisms involved in the
antitumor potential of CLA stated that these fatty acids
had strong antioxidant activities. In vitro research has sug-
gested that CLA anticancer activity might be partially
mediated by inducing lipid peroxidation [16].
The evidence supports the potential role of antioxidant
agents in cancer prevention since they are scavengers for
organic free radicals and so prevent the tissue damage.
Although epidemiologic studies are not entirely consist-
ent, many show an inverse relationship between dietary
intake or blood levels of antioxidants contained in foods
and cancer risk [17].
Dietary modifications of cattle forage. Influence of CLA, 
PUFAs and saturated fats levels on ruminant lipid tissues
The cis-9, trans-11 isomer is the principal dietary form of
CLA, but the concentrations of this isomer and the trans-
10, cis-12 isomer in dairy products or beef vary depending
on the diet offered to cows or steers, respectively [18].
Decreasing the proportion of manipulated concentrates in
the diet of steers, along with increased grass intake caused
a desirable decrease in the concentration of intramuscular
saturated fatty acid (SFA) and in the n-6 /n-3 PUFA ratio,
together with an increase in the PUFA:SFA ratio and CLA
concentration. The data indicate that intramuscular fatty
acid composition of beef can be improved for healthy
human nutrition by replacing manufactured food supple-
ments by natural grass in the diet [19]. In non-ruminants,
such as rodents, dietary CLA supplementation signifi-
cantly reduced energy intake, growth rate, adipose depot
weight and carcass lipid content independent of other die-
tary lipids. Overall, the reduction of adipose depot weight
ranged from 43 to 88% [20].
Dietary fatty acid sources also affect CLA concentrations in
milk from lactating cows. CLA concentration in milk fat
can be enhanced by the addition of polyunsaturated fatty
acid (PUFA) to the diet, especially oils high in 18:2 n-6
[21]. Diets rich in 18:3 n-3 can increase the CLA content
in milk when dietary sources of this oil are accessible to
the rumen microorganisms [22].
Experimental models
CLA behaves as a powerful anticarcinogen in a rat tumor
model with an effective range as low as 0.5% in the diet.
F344 rats were initiated with the carcinogen 2-amino-3-
methylimidazol [4,5-f] quinolone (IQ) in order to induce
colon carcinogenesis. CLA was administered to male rats
by gavages followed by IQ. Aberrant crypt foci (ACF) were
quantified in colon glands. While CLA administration
had no impact on the size of ACF, their number was sig-
nificantly reduced in the CLA group [23]. Interestingly,
the protective effect of CLA is expressed at concentrations
close to human consumption levels [24].
Table 1: Proportions of Total fats, saturated fats plus cholesterol with respect to CLA in fatty or lean beef.
MEATS TF S F A CH CLA CLA/ SFA + CH
LEAN 15.40 6.52 0.065 0.62 0.09
FATTY 37.40 15.82 0.09 0.12 0.007
Total fats (TF); Saturated fats (SFA); Cholesterol (CH); Conjugated linoleic acid (CLA) expressed as g of the lipid/100 g of meats, taken from 
reference [14]. Values of CLA were expressed as averages from data of Ma DW et al [15].Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/6
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Other experimental evidence shows that dietary CLA
inhibits azoxymethane-induced colonic aberrant crypt
foci in male rats. The administration of CLA caused a sig-
nificant reduction in the frequency of ACF. Also, these
mixtures of trans isomers lowered the proliferating cell
nuclear antigen (PCNA) index in colonic ACF whereas
apoptosis occurred in the cells of ACF [25]. Park et al
reported that dietary CLA can inhibit 1.2-dimethylhydra-
zine-induced colon carcinogenesis by a mechanism prob-
ably involving increased apoptosis. These authors
suggested a possible chemopreventive activity of CLA in
the early phase of colon tumorigenesis through modula-
tion of cryptal cell proliferation activity and apoptosis
[26]. As shown, the beneficial effects of CLA as antitumor
food are observed for a broad range of chemical
carcinogens.
In vitro assay
Several studies have demonstrated in vitro anticancer
activity for CLA, with this being cytotoxic to human
malignant melanoma, breast, lung and colorectal cancer
cell lines [27]. The incubation with CLA showed a signifi-
cant reduction in the proliferation of colorectal cell HT-29
compared to control cultures [28]. CLA has shown inhib-
itory effects in cellular growth suppression of human
SW480 colon cancer cells and breast cancer MCF-7, being
CLA preferentially incorporated into the phospholipid
fraction of the MCF-7 cell lipids. The increase in lipid per-
oxidation observed in CLA-treated cells suggests that CLA
may reverse the resistance to the oxidative stress character-
istic of cancer cells.[29]
Clinical and epidemiological approaches
There is insufficient evidence from human epidemiologi-
cal data to form a useful guide for nutritional recommen-
dations. Very few of the animal studies have shown a
dose-response relationship to the amount of CLA fed and
the extent of tumor growth. Development of CRC has
been suggested to be closely related to environmental
exposure, especially that arising from the diet [30]. Exper-
imental studies in animals and research on human beings
have demonstrated that an increase of body fat mass is
linked to increased risk of CRC. Obesity has been associ-
ated with an increased risk of cancer at a number of sites,
including endometrium, postmenopausal breast cancer,
pancreas, prostate and colon. There is strong evidence that
a high risk of CRC is associated with obesity together
other factors including and with a low intake of vegeta-
bles, whole grain cereals and fish [31]. It is also possible
that one of the antitumoral effects adscribed to CLA may
be linked to its capability of weight reduction.
Epidemiological studies suggest that whole milk and
derived milk products, rich in CLA, fit well into a healthy
eating pattern because CLA, besides its antitumor proper-
ties, is hypolipidaemic and antioxidative and is therefore
an antiatherosclerotic nutrient [32].
Other anticarcinogens such as butyric acid, sphingomye-
lin, ether lipids and metabolites of tumor supressor lipids
are also present in milk fat, and these may act in conjunc-
tion with CLA, thus making the consumption of whole
milk and dairy derivatives beneficial [33].
Implications of the hypothesis
CLA-enriched milk fats may be used on a larger scale to
produce CLA-enriched products, such as milk, butter,
cheese and yoghurt. Consumption of such natural prod-
ucts may produce a natural chemopreventive effect, with-
out the additional cost of oral supplements or the need for
disturbing dietary changes [27,34].
In conclusion, the challenge for nutritionists, physicians
and dairy product producers is to improve the quality of
healthy meat and milk derivatives, thereby obtaining
lower levels of saturated fats and cholesterol, along with
desirably higher levels of CLA and n-3 PUFAS. This task is
challenging since taste and flavour must be maintained at
acceptable levels.
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